FDA Puts Abortion Pill Review on Hold Until After Elections

The FDA has decided to postpone a safety review of the abortion drug mifepristone until after the midterm elections. This delay was requested by FDA Commissioner Marty Makary, despite earlier claims that the review was actively underway.

The Health and Human Services Department stated that their scientific reviews take time to ensure accuracy.

Growing Divide on Abortion Policies in the U.S.

The U.S. is seeing a growing divide between states on abortion policies. Experts note that despite these policy changes, women will still seek abortion care.

Meanwhile, Congress has removed a provision for IVF coverage in the military's defense bill, which has upset many lawmakers and advocates.

Impact of "Forever Chemicals" on Infant Health

A recent study found that mothers exposed to "forever chemicals" in New Hampshire had higher rates of infant deaths and premature births. These chemicals, known as PFAS, have been linked to serious health issues.

Additionally, many Americans are concerned about falling birth rates, with some worried about the future of the country's population.

New Policies Supporting Parents and Infants

In Indiana, a new policy allows state employees to bring their infants to work until they are six months old. This policy aims to support working parents, though some experts argue that caring for a newborn is already a full-time job.

Meanwhile, cochlear implants are now available for babies as young as seven months, providing life-changing benefits for hearing-impaired children.